Char Eye Ear &Throat Assoc

Charlotte, North Carolina 28210

0 studies enrolling now · 16 studies all time

What they study most

Choroidal Neovascularization, Diabetic Macular Edema, Geographic Atrophy, Macular Degeneration, Macular Edema, Neovascular Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration

Studies at this site

• Extension Study for the Port Delivery System With Ranibizumab (Portal) — Recruiting now
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema — Completed
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA) — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) — Completed
• A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration — Completed
• Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration — Completed
• A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) — Completed
• A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema — Completed
• A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy — Completed
• An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy — Stopped early
• A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) — Stopped early
• A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS) — Completed